Aduro is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases.
September 19, 2018 Aduro Biotech Announces the Departure of Natalie R. Sacks, M.D.
Data provided by Nasdaq. Minimum 15 minutes delayed.